Secondary Logo

Institutional members access full text with Ovid®

Expression of nuclear factor-erythroid 2-related factor 2 in rat brain following the administration of kainic acid and pentylenetetrazole

Ruíz-Díaz, Amairania; Manjarrez, Joaquínb; Nava-Ruíz, Concepcióna; Zaga-Clavellina, Verónicac; Flores-Espinosa, Pilarc; Díaz-Ruíz, Aracelid; Yescas-Gómez, Petrae; Méndez-Armenta, Mariselaa

doi: 10.1097/WNR.0000000000001207
DEGENERATION AND REPAIR
Buy
SDC

Epilepsy is a neurological disorder of the central nervous system characterized by hypersynchronized neuronal activity and has been associated with oxidative stress. Oxidative stress interferes with the expression of genes as well as transcriptional factors such as nuclear factor-erythroid 2-related factor 2 (Nrf2). We evaluated the expression of Nrf2 in the rat brain in treated with kainic acid (KA) and pentylenetetrazole (PTZ). Nrf2 immunoreactivity was observed in astrocytes of the hippocampal region in rats exposed at KA. Nrf2 expression was increased significantly in rats with KA and PTZ. These results provide evidence that the increased expression of Nrf2 is part of the mechanism against KA and PTZ toxicity.

aExperimental Neuropathology Laboratory, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez

bReticular Formation Laboratory, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez

cCell Biology Laboratory, Instituto Nacional de Perinatología, Isidro Espinosa de los Reyes

dDepartment of Neurochemistry, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez

eDepartment of Neurogenetics, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez

Correspondence to Marisela Méndez-Armenta, PhD, Experimental Neuropathology Laboratory, National Institute of Neurology and Neurosurgery, Manuel Velasco Suárez. Insurgentes Sur 3877 La Fama, Tlalpan. CP14269 México D.F. MEXICO Tel: +52 155 5606 3822; e-mail: mmendezarmenta@hotmail.com

Received December 5, 2018

Accepted December 26, 2018

© 2019 Wolters Kluwer Health | Lippincott Williams & Wilkins